Blockade of the metabotropic glutamate (mGluR2) modulates arousal through vigilance states transitions: Evidence from sleep-wake EEG in rodents

被引:25
作者
Ahnaou, A. [1 ]
Donck, L. Ver [1 ]
Drinkenburg, W. H. I. M. [1 ]
机构
[1] Janssen Res & Dev, Dept Neurosci, B-2340 Beerse, Belgium
关键词
mGluR2; Arousal behavior; Theta/gamma oscillations; States transition; Rodents; Psychiatric disorders; CENTRAL-NERVOUS-SYSTEM; MOOD DISORDERS; REM-SLEEP; ALLOSTERIC MODULATOR; RECEPTOR ANTAGONIST; THETA RHYTHM; RAT; DEPRESSION; ANTIDEPRESSANTS; MICE;
D O I
10.1016/j.bbr.2014.05.003
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Accumulating data continue to support the therapeutic potential of glutamate metabotropic (mGluR2) receptors for treatment of psychiatric disorders such as depression, anxiety and schizophrenia. Glutamate neurotransmission is an integral component of sleep wake mechanisms, which have translational relevance to assess on-target activity of drugs. Here, we investigated the influence of mGluR2 inactivation upon sleep-wake electroencephalogram (EEG) in rodents. Rats were administered with vehicle, the specific mGluR2 antagonist LY341495 (2.5, 5, 10 mg/kg) or negative allosteric modulator (NAM) Ro-4491533 (2.5, 10 and 40 mg/kg) at lights onset. mGluR2 (-/-) mice were used to confirm the selectivity of functional response. Both LY341495 and Ro-4491533 induced an immediate and endured desynchronized cortical activity during 3-6h associated with enhanced theta and gamma oscillations and depressed slow oscillations during sleep. The arousal-promoting effect is consistent with the marked lengthening of sleep onset latency, an increased number of state transitions from light sleep to waking and the gradual increase in homeostatic compensatory sleep. The arousal response to mGluR2 blockade was not accompanied by sharp rebound hypersomnolence as found with the classical psycho-stimulant amphetamine. mGluR2 (-/-) mice and their WT littermates exhibited similar sleep wake phenotype, while Ro-4491533 (40 mg/kg) enhanced waking associated with increased locomotor activity and body temperature in WT but not in mGluR2 (-/-) mice, which confirm the role of mGluR2 inactivation in the arousal response. Our results lend support for a role of mGluR2 blockade in promoting cortical arousal associated with theta/gamma oscillations as well as high thresholds transitions from sleep to waking. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:56 / 67
页数:12
相关论文
共 61 条
[11]   Targeting of Metabotropic Glutamate Receptors for the Treatment of Schizophrenia [J].
Chaki, Shigeyuki ;
Hikichi, Hirohiko .
CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (02) :94-102
[12]  
Colgin LL, 2011, CURR OPIN NEUROBIOL, V21, P467, DOI 10.1016/j.conb.2011.04.006
[13]   Promise of mGluR2/3 activators in psychiatry [J].
Conn, P. Jeffrey ;
Jones, Carrie K. .
NEUROPSYCHOPHARMACOLOGY, 2009, 34 (01) :248-249
[14]   Microinjection of glutamate into the pedunculopontine tegmentum induces REM sleep and wakefulness in the rat [J].
Datta, S ;
Spoley, EE ;
Patterson, EH .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 280 (03) :R752-R759
[15]   Effects of microinjections of Group II metabotropic glutamate agents into the amygdala on sleep [J].
Dong, Enheng ;
Wellman, Laurie L. ;
Yang, Linghui ;
Sanford, Larry D. .
BRAIN RESEARCH, 2012, 1452 :85-95
[16]   Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders [J].
Drevets, WC .
CURRENT OPINION IN NEUROBIOLOGY, 2001, 11 (02) :240-249
[17]  
Edgar DM, 1997, J PHARMACOL EXP THER, V283, P757
[18]  
Fava M, 2004, J CLIN PSYCHIAT, V65, P27
[19]   The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist LY379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats [J].
Feinberg, I ;
Schoepp, DD ;
Hsieh, KC ;
Darchia, N ;
Campbell, IG .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (02) :826-833
[20]   N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide(THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neurochemical Changes [J].
Fell, Matthew J. ;
Witkin, Jeffrey M. ;
Falcone, Julie F. ;
Katner, Jason S. ;
Perry, Kenneth W. ;
Hart, John ;
Rorick-Kehn, Linda ;
Overshiner, Carl D. ;
Rasmussen, Kurt ;
Chaney, Stephen F. ;
Benvenga, Mark J. ;
Li, Xia ;
Marlow, Deanna L. ;
Thompson, Linda K. ;
Luecke, Susan K. ;
Wafford, Keith A. ;
Seidel, Wesley F. ;
Edgar, Dale M. ;
Quets, Anne T. ;
Felder, Christian C. ;
Wang, XuShan ;
Heinz, Beverly A. ;
Nikolayev, Alexander ;
Kuo, Ming-Shang ;
Mayhugh, Daniel ;
Khilevich, Albert ;
Zhang, Deyi ;
Ebert, Philip J. ;
Eckstein, James A. ;
Ackermann, Bradley L. ;
Swanson, Steven P. ;
Catlow, John T. ;
Dean, Robert A. ;
Jackson, Kimberley ;
Tauscher-Wisniewski, Sitra ;
Marek, Gerard J. ;
Schkeryantz, Jeffrey M. ;
Svensson, Kjell A. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 336 (01) :165-177